339 related articles for article (PubMed ID: 26269601)
21. Abl kinase regulation by BRAF/ERK and cooperation with Akt in melanoma.
Jain A; Tripathi R; Turpin CP; Wang C; Plattner R
Oncogene; 2017 Aug; 36(32):4585-4596. PubMed ID: 28368422
[TBL] [Abstract][Full Text] [Related]
22. Overcoming acquired BRAF inhibitor resistance in melanoma via targeted inhibition of Hsp90 with ganetespib.
Acquaviva J; Smith DL; Jimenez JP; Zhang C; Sequeira M; He S; Sang J; Bates RC; Proia DA
Mol Cancer Ther; 2014 Feb; 13(2):353-63. PubMed ID: 24398428
[TBL] [Abstract][Full Text] [Related]
23. NRG1 / ERBB3 signaling in melanocyte development and melanoma: inhibition of differentiation and promotion of proliferation.
Buac K; Xu M; Cronin J; Weeraratna AT; Hewitt SM; Pavan WJ
Pigment Cell Melanoma Res; 2009 Dec; 22(6):773-84. PubMed ID: 19659570
[TBL] [Abstract][Full Text] [Related]
24. Neuregulin/erythroblastic leukemia viral oncogene homolog 3 autocrine loop contributes to invasion and early recurrence of human hepatoma.
Hsieh SY; He JR; Hsu CY; Chen WJ; Bera R; Lin KY; Shih TC; Yu MC; Lin YJ; Chang CJ; Weng WH; Huang SF
Hepatology; 2011 Feb; 53(2):504-16. PubMed ID: 21246584
[TBL] [Abstract][Full Text] [Related]
25. Synchronized Targeting of Notch and ERBB Signaling Suppresses Melanoma Tumor Growth through Inhibition of Notch1 and ERBB3.
Zhang K; Wong P; Salvaggio C; Salhi A; Osman I; Bedogni B
J Invest Dermatol; 2016 Feb; 136(2):464-472. PubMed ID: 26967479
[TBL] [Abstract][Full Text] [Related]
26. Stat3-targeted therapies overcome the acquired resistance to vemurafenib in melanomas.
Liu F; Cao J; Wu J; Sullivan K; Shen J; Ryu B; Xu Z; Wei W; Cui R
J Invest Dermatol; 2013 Aug; 133(8):2041-9. PubMed ID: 23344460
[TBL] [Abstract][Full Text] [Related]
27. BRAF
Lunavat TR; Cheng L; Einarsdottir BO; Olofsson Bagge R; Veppil Muralidharan S; Sharples RA; Lässer C; Gho YS; Hill AF; Nilsson JA; Lötvall J
Proc Natl Acad Sci U S A; 2017 Jul; 114(29):E5930-E5939. PubMed ID: 28684402
[TBL] [Abstract][Full Text] [Related]
28. The plasma membrane Ca
Hegedũs L; Garay T; Molnár E; Varga K; Bilecz Á; Török S; Padányi R; Pászty K; Wolf M; Grusch M; Kállay E; Döme B; Berger W; Hegedũs B; Enyedi A
Int J Cancer; 2017 Jun; 140(12):2758-2770. PubMed ID: 27813079
[TBL] [Abstract][Full Text] [Related]
29. ROS production induced by BRAF inhibitor treatment rewires metabolic processes affecting cell growth of melanoma cells.
Cesi G; Walbrecq G; Zimmer A; Kreis S; Haan C
Mol Cancer; 2017 Jun; 16(1):102. PubMed ID: 28595656
[TBL] [Abstract][Full Text] [Related]
30. ROCK1 is a potential combinatorial drug target for BRAF mutant melanoma.
Smit MA; Maddalo G; Greig K; Raaijmakers LM; Possik PA; van Breukelen B; Cappadona S; Heck AJ; Altelaar AF; Peeper DS
Mol Syst Biol; 2014 Dec; 10(12):772. PubMed ID: 25538140
[TBL] [Abstract][Full Text] [Related]
31. Metabolic targeting synergizes with MAPK inhibition and delays drug resistance in melanoma.
Brummer C; Faerber S; Bruss C; Blank C; Lacroix R; Haferkamp S; Herr W; Kreutz M; Renner K
Cancer Lett; 2019 Feb; 442():453-463. PubMed ID: 30481565
[TBL] [Abstract][Full Text] [Related]
32. BRAF inhibitor resistance mediated by the AKT pathway in an oncogenic BRAF mouse melanoma model.
Perna D; Karreth FA; Rust AG; Perez-Mancera PA; Rashid M; Iorio F; Alifrangis C; Arends MJ; Bosenberg MW; Bollag G; Tuveson DA; Adams DJ
Proc Natl Acad Sci U S A; 2015 Feb; 112(6):E536-45. PubMed ID: 25624498
[TBL] [Abstract][Full Text] [Related]
33. Hypoxia increases the heterogeneity of melanoma cell populations and affects the response to vemurafenib.
Pucciarelli D; Lengger N; Takáčová M; Csaderova L; Bartosova M; Breiteneder H; Pastorekova S; Hafner C
Mol Med Rep; 2016 Apr; 13(4):3281-8. PubMed ID: 26936534
[TBL] [Abstract][Full Text] [Related]
34. BRAF
Feng L; Li J; Bu X; Zuo Y; Shen L; Qu X
Biochem Biophys Res Commun; 2020 Mar; 524(1):28-35. PubMed ID: 31980175
[TBL] [Abstract][Full Text] [Related]
35. Targeting the NRG1/HER3 pathway in tumor cells and cancer-associated fibroblasts with an anti-neuregulin 1 antibody inhibits tumor growth in pre-clinical models of pancreatic cancer.
Ogier C; Colombo PE; Bousquet C; Canterel-Thouennon L; Sicard P; Garambois V; Thomas G; Gaborit N; Jarlier M; Pirot N; Pugnière M; Vie N; Gongora C; Martineau P; Robert B; Pèlegrin A; Chardès T; Larbouret C
Cancer Lett; 2018 Sep; 432():227-236. PubMed ID: 29935372
[TBL] [Abstract][Full Text] [Related]
36. Dramatic response of vemurafenib-induced cutaneous lesions upon switch to dual BRAF/MEK inhibition in a metastatic melanoma patient.
Peters S; Bouchaab H; Zimmerman S; Bucher M; Gaide O; Letovanec I; Homicsko K; Michielin O
Melanoma Res; 2014 Oct; 24(5):496-500. PubMed ID: 25185693
[TBL] [Abstract][Full Text] [Related]
37. BRAF Inhibition Generates a Host-Tumor Niche that Mediates Therapeutic Escape.
Fedorenko IV; Wargo JA; Flaherty KT; Messina JL; Smalley KSM
J Invest Dermatol; 2015 Dec; 135(12):3115-3124. PubMed ID: 26302068
[TBL] [Abstract][Full Text] [Related]
38. Shifting the Balance of Activating and Inhibitory Natural Killer Receptor Ligands on
Frazao A; Colombo M; Fourmentraux-Neves E; Messaoudene M; Rusakiewicz S; Zitvogel L; Vivier E; Vély F; Faure F; Dréno B; Benlalam H; Bouquet F; Savina A; Pasmant E; Toubert A; Avril MF; Caignard A
Cancer Immunol Res; 2017 Jul; 5(7):582-593. PubMed ID: 28576831
[TBL] [Abstract][Full Text] [Related]
39.
Kulkarni A; Al-Hraishawi H; Simhadri S; Hirshfield KM; Chen S; Pine S; Jeyamohan C; Sokol L; Ali S; Teo ML; White E; Rodriguez-Rodriguez L; Mehnert JM; Ganesan S
Clin Cancer Res; 2017 Sep; 23(18):5631-5638. PubMed ID: 28539463
[No Abstract] [Full Text] [Related]
40. Constitutive activation of neuregulin/ERBB3 signaling pathway in clear cell sarcoma of soft tissue.
Schaefer KL; Brachwitz K; Braun Y; Diallo R; Wai DH; Zahn S; Schneider DT; Kuhnen C; Vollmann A; Brockhoff G; Gabbert HE; Poremba C
Neoplasia; 2006 Jul; 8(7):613-22. PubMed ID: 16867224
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]